期刊文献+

硫酸寡糖复合物对人结肠癌SW620细胞迁移与侵袭能力的影响 被引量:2

Effect of sulfated oligosaccharide phosphomannopentaose sulfate on the migration and invasion of colon cancer SW620 cells
原文传递
导出
摘要 目的探讨硫酸寡糖复合物(PI-88)对结肠癌SW620细胞迁移与侵袭的影响及机制。方法培养人结肠癌SW620细胞,分为对照组、溶媒组和药物组;对照组细胞不做任何处理,药物组细胞给予5μL的0.5mol/L的PI-88,溶媒组给予细胞5μL的磷酸盐缓冲液(PBS)。各组细胞处理后继续培养24h,采用划痕实验检测结肠癌SW620细胞迁移距离;Transwell小室检测结肠癌SW620细胞迁移数量与侵袭数量;Westernblot检测结肠癌SW620细胞中乙酰肝素酶(HPA)、血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)蛋白的表达。结果划痕实验结果显示,药物组SW620细胞迁移距离(35.49±6.89)μm小于对照组(216.75±21.43)μm、溶媒组(227.52±17.72)μm,差异均有统计学意义(P值均<0.05)。Transwell小室细胞迁移、侵袭实验结果显示,药物组SW620细胞迁移数目(226±37)个和侵袭数目(89±11)个均少于对照组(875±93、321±28)个和溶媒组(843±116、331±43)个,差异均有统计学意义(P值均<0.05)。Westernblot实验结果显示,药物组PHA、VEGF、bFGF蛋白相对表达量均明显低于对照组和溶媒组,差异均有统计学意义(P值均<0.05)。结论PI-88具有抑制结肠癌SW620细胞迁移与侵袭的作用,其作用机制可能与PI-88抑制结肠癌SW620细胞HPA、VEGF、bFGF蛋白的表达有关。 Objective To explore the effects and the mechanism of sulfated oligosaccharide phosphomannopentaose sulfate (PI-88) on invasion and migration of colon cancer SW620 cells. Methods Colon cancer SW620 cells were cultured and further divided into control group, solvent group and drug group. The cells in the control group were treated without any treatment, the cells in the drug group were treated with 0.5 mol/L PI-88 5μL, and the cells in the solvent group were treated with 5 μL PBS of equal volume. The cells of each group were cultured for 24 h after treatment. The migration distance of colon cancer SW620 cells were analyzed by wound healing assay. The number of migration and invasion of colon cancer SW620 cells were analyzed by Transwell assay. Finally, the protein expressions of heparanase(HPA), vascular endothelial growth factor (VEGF) and basic fibroblast growth factor ( bFGF) in colon cancer SW620 cells were detected by Western blot assay. Results The data of wound healing assay showed that the migration distance of SW620 cells in the drug group(35.49±6.89)μm was less than that in the control group(216.75±21.43)μm and the solvent group(227.52±17.72)μm, and the difference was statistically significant(all P values <0.05). The data of Transwell assay showed that the number of migration(226±37) and invasion(89±11) of colon cancer SW620 cells in the drug group were less than those in the control group(875±93, 321±28) and the solvent group(843±116, 331±43), and the difference was statistically significant(all P values<0.05). Moreover, the data of Western blot showed that the protein expressions of HPA, VEGF and bFGF in the drug group were decreased than those in the control group and the solvent group, and the differences were statistically significant(all P values<0.05). Conclusions PI-88 inhibits colon cancer cell migration and invasion, the mechanism may be related to the inhibition of HPA, VEGF and bFGF protein expressions.
作者 张磊 吴慧丽 肖兴国 李琨琨 张利 张超 Zhang Lei;Wu Huili;Xiao Xingguo;Li Kunkun;Zhang Li;Zhang Chao(Department of Gastroenterology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou 450000, China)
出处 《中华解剖与临床杂志》 2018年第6期543-547,共5页 Chinese Journal of Anatomy and Clinics
基金 河南省科技攻关计划项目 (162102310228).
关键词 结肠肿瘤 硫酸寡糖复合物 侵袭 迁移 SW620细胞 Colonic neoplasms Sulfated oligosaccharide phosphomannopentaose sulfate Invasion Migration SW620 cells
  • 相关文献

参考文献2

二级参考文献11

  • 1Josep M Llovet,Andrew Burroughs,Jordi Bruix.Hepatocellular carcinoma[J]. The Lancet . 2003 (9399)
  • 2Ann-Lii Cheng,Yoon-Koo Kang,Zhendong Chen,Chao-Jung Tsao,Shukui Qin,Jun Suk Kim,Rongcheng Luo,Jifeng Feng,Shenglong Ye,Tsai-Sheng Yang,Jianming Xu,Yan Sun,Houjie Liang,Jiwei Liu,Jiejun Wang,Won Young Tak,Hongming Pan,Karin Burock,Jessie Zou,Dimitris Voliotis,Zhongzhen Guan.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial[J].Lancet Oncology.2009(1)
  • 3Sheung Tat Fan,Chung Mau Lo,Ronnie T. P. Poon,Chun Yeung,Chi Leung Liu,Wai Key Yuen,Chi Ming Lam,Kelvin K. C. Ng,See Ching Chan.Continuous Improvement of Survival Outcomes of Resection of Hepatocellular Carcinoma: A 20-Year Experience[J].Annals of Surgery.2011(4)
  • 4Roberto Gedaly,Paul Angulo,Jonathan Hundley,Michael F. Daily,Changguo Chen,B. Mark Evers.PKI-587 and Sorafenib Targeting PI3K/AKT/mTOR and Ras/Raf/MAPK Pathways Synergistically Inhibit HCC Cell Proliferation[J].Journal of Surgical Research.2012(2)
  • 5Luca Faloppi,Mario Scartozzi,Elena Maccaroni,Marzia Di Pietro Paolo,Rossana Berardi,Michela Del Prete,Stefano Cascinu.Evolving strategies for the treatment of hepatocellular carcinoma: From clinical-guided to molecularly-taylored therapeutic options[J].Cancer Treatment Reviews.2010(3)
  • 6Chun-Jen Liu,Po-Huang Lee,Deng-Yn Lin,Cheng-Chung Wu,Long-Bin Jeng,Pin-Wen Lin,King-Tong Mok,Wei-Chen Lee,Hong-Zen Yeh,Ming-Chih Ho,Sheng-Shun Yang,Ching-Chih Lee,Ming-Chin Yu,Rey-Heng Hu,Cheng-Yuan Peng,Kuan-Lang Lai,Stanley Shi-Chung Chang,Pei-Jer Chen.Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage[J].Journal of Hepatology.2009(5)
  • 7Alejandro Forner,Sasan Roayaie.Clinical research in hepatocellular carcinoma: Study design and endpoints[J].Journal of Hepatology.2009(5)
  • 8Hiroshi Ishii,Junji Yamamoto,Takaaki Ikari.Adjuvant treatments for resectable hepatocellular carcinoma[J].Journal of Hepato - Biliary - Pancreatic Surgery.2008(5)
  • 9Jonathan D Schwartz,Myron Schwartz,John Mandeli,Max Sung.Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials[J].Lancet Oncology.2002(10)
  • 10Ronnie Tung-Ping Poon,Sheung-Tat Fan,John Wong.Risk Factors, Prevention, and Management of Postoperative Recurrence After Resection of Hepatocellular Carcinoma[J].Annals of Surgery.2000(1)

共引文献23

同被引文献19

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部